NCT07281417 2026-03-18
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
14 trialsNCT07479628 2026-03-18
Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT07472868 2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3 Not yet recruiting
NCT06984861 2026-03-09
A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07209189 2026-03-09
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06647680 2026-03-06
Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）
The Affiliated Hospital of Qingdao University
Phase 2 Recruiting
NCT00707473 2026-03-05
Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03609216 2026-03-04
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT04215731 2026-03-03
FOBEAR
Sun Yat-sen University
Phase 3 Recruiting
NCT06452602 2026-02-27
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT04913311 2026-02-19
Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Recruiting
NCT06059261 2026-02-18
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
Chongqing University Cancer Hospital
Phase 2 Recruiting
NCT03051464 2026-02-17
Morpheus
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2/3 Recruiting
NCT07407205 2026-02-17
Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal Cancer
Institute of Oncology Ljubljana
Phase NA Active not recruiting